Israel - English - Ministry of Health

abic marketing ltd, israel - lamivudine - tablets - lamivudine 100 mg - lamivudine - lamivudine - lamivudine is indicated for the treatment of chronic hepatitis b associated with the evidence of hepatitis b viral (hbv) replication and active liver inflammation in aduls and also in children and adolescents aged 2 to 17 years old.

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

European Union - English - EMA (European Medicines Agency)

teva b.v. - lamivudine - hepatitis b, chronic - antivirals for systemic use - lamivudine teva is indicated for the treatment of chronic hepatitis b in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active liver inflammation and / or fibrosis. initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablet is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-l) infection.   limitation of use: the dosage of this product is for hiv-1and not for hbv. lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. teratogenic effects pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry at 1-800-258-4263.  risk summary available data from the antiretroviral pregnancy registry show no difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% in the us reference population of the metropolitan atlanta congenital defects program (macdp). lamivudine produced embryonic toxicity in rabbits at

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. lamivudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the product. pregnancy category c. there are no adequate and well-controlled studies of lamivudine in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. lamivudine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics in: 16 women at 36 weeks gestation usin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lamivudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lamivudine -